Año 2022 / Volumen 114 / Número 6
Editorial
Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters

312-313

DOI: 10.17235/reed.2022.8902/2022

Paolo De Simone, Jessica Bronzoni, Caterina Martinelli,

Resumen
The current edition of the journal features a Spanish, nationwide, multi-institutional study by Gomez Bravo MA et al. exploring the advantages of everolimus (EVR)-facilitated tacrolimus (TAC) minimization versus TAC in combination with mycophenolate mofetil (MMF) after liver transplantation (LT).
Share Button
Nuevo comentario
Comentarios

21/06/2022 0:57:07
Am here to appreciate Dr.Timothy for using his herbal medicine to cure my Herpes virus. since 2016 i have been living with this virus and it has been giving me challenges, I was so perplexed cause i have been taking several drugs to be cured but all of my effort was in vain,one evening i was browsing through the internet then i saw several testimonies about Dr.Timothy curing people from Herpes virus and immediately i contacted his email address i told him about my sickness and he told me that i will be cured within 21 days he gave me some instructions and which i rightly followed. so he prepared a herbal medicine for me and sent it to me which i used for 21 days and everything was like a dream to me and my Herpes virus was totally gone why don't you contact Dr.Timothy he is very good and honest. contact him via email address; goodhealthherbalfoundation@yahoo.com OR website https://5dc41d5b6d60d.site123.me


Bibliografía
1. Gomez Bravo MA, Prieto M, Navasa M, et al. Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. Rev Esp Enf Dig 2022, in press.
2. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012;12(11):3008-3020.
3. Jeng LB, Lee SG, Soin AS, et al. Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study. Am J Transplant 2017;18(6):1435-1446.
4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl. 2013; 3: 1–150.
5. Allen AM, Kim WR, Therneau TM, et al. Chronic kidney disease and associated mortality after liver transplantation – a time-dependent analysis using measured glomerular filtration rate. J Hepatol 2014;61(2):286-92.
6. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012;12(7):1855-1865.
7. Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014;14(3):701-710.
8. Sterneck M, Kaiser GM, Heyne N, et al. Long-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study. Clin Transplant 2016;30(6):741-748.
9. De Simone P, Carrai P, Coletti L, et al. Everolimus vs mycophenolate mofetil in combination with tacrolimus: a propensity score-matched analysis in liver transplantation. Transplant Proc 2018;50(10):3615-3620.
10. Tedesco-Silva H, Saliba F, Barten MJ, et al. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients. Transplant Rev (Orlando) 2022; 36(1):100655.
11. Lassailly G, Dumortier J, Saint-Marcoux F, et al. Real life experience of mycophenolate mofetil monotherapy in liver transplant patients. Clin Res Hepatol Gastroenterol 2021; 45(1):101451.
12. Norero B, Serrano CA, Sanchez-Fueyo A, et al. Conversion to mycophenolate mofetil monotherapy in liver recipients: Calcineurin inhibitor levels are key. Ann Hepatol 2017; 16(1):94-106.
13. Cruz CM, Pereira S, Gandara J, et al. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation patients with nephrotoxicity. Transplant Proc 2016; 48(7): 2341-3.
14. Holdaas H, De Simone P, Zuckermann A. Everolimus and malignancy after solid organ transplantation: A clinical update. J Transplant 2016; 2016:4349574.
15. Ferrín G, Guerrero M, Amado V, et al. Activation of mTOR signaling pathway in hepatocellular carcinoma. Int J Mol Sci 2020; 21(4):E1266.
Artículos relacionados

Imagen en Patología Digestiva

Síndrome de encefalopatía posterior reversible (PRES) en el postrasplante hepático

DOI: 10.17235/reed.2022.8694/2022

Carta

Neurotoxicidad por ertapenem

DOI: 10.17235/reed.2021.8469/2021

Carta

EBVMCU in a liver-transplant patient

DOI: 10.17235/reed.2021.8064/2021

Imagen en Patología Digestiva

Hepatitis enfisematosa: una entidad muy infrecuente y de mal pronóstico

DOI: 10.17235/reed.2021.7795/2021

Revisión

La fragilidad física en el contexto del trasplante hepático

DOI: 10.17235/reed.2020.7448/2020

Carta

Manejo de los aneurismas de la arteria hepática

DOI: 10.17235/reed.2020.7219/2020

Imagen en Patología Digestiva

Hemangioendotelioma epitelioide como causa infrecuente de tumor hepático

DOI: 10.17235/reed.2020.7127/2020

Carta

Hepatitis aguda C seronegativa: informe de dos casos

DOI: 10.17235/reed.2019.5921/2018

Carta al Editor

Post-transplant lymphoproliferative disease after liver transplantation

DOI: 10.17235/reed.2017.5387/2017

Original

Síndrome linfoproliferativo en el trasplante hepático

DOI: 10.17235/reed.2017.4228/2016

Caso Clínico

IBD or strongyloidiasis?

DOI: 10.17235/reed.2015.3847/2015

Instrucciones para citar
De Simone P, Bronzoni J, Martinelli C. Everolimus versus mycophenolate mofetil in liver transplantation: every improvement in renal function matters . 8902/2022


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 920 veces.
Este artículo ha sido descargado 198 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 02/05/2022

Aceptado: 03/05/2022

Prepublicado: 12/05/2022

Publicado: 07/06/2022

Tiempo de prepublicación: 10 días

Tiempo de edición del artículo: 36 días


Compartir
Este artículo ha sido valorado por 1 lectores .
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas